{
  "meta": {
    "title": "20_Stds_And_Surface_Infections",
    "url": "https://brainandscalpel.vercel.app/20-stds-and-surface-infections-1aa46cb2.html",
    "scrapedAt": "2025-11-30T12:26:56.660Z"
  },
  "questions": [
    {
      "text": "When is World AIDS day observed?",
      "choices": [
        {
          "id": 1,
          "text": "March 24th"
        },
        {
          "id": 2,
          "text": "February 4th"
        },
        {
          "id": 3,
          "text": "December 1st"
        },
        {
          "id": 4,
          "text": "April 25th"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The<strong> World AIDS Day</strong> is observed on <strong>December 1st</strong>. The theme for 2021 is 'Ending the HIV epidemic: Equitable Access, Everyone&rsquo;s Voice'.</p>\n<p>Option A: &nbsp;The World Tuberculosis Day is on&nbsp;March 24.</p>\n<p>Option B: &nbsp;The World Cancer Day is on&nbsp;February 4.</p>\n<p>Option D: The World Malaria Day&nbsp;is on April 25.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8151",
      "difficulty": "easy"
    },
    {
      "text": "What are the most common modes of transmission of HIV in India in descending order?",
      "choices": [
        {
          "id": 1,
          "text": "Transplacental, homosexual, heterosexual"
        },
        {
          "id": 2,
          "text": "Homosexual, heterosexual, transplacental"
        },
        {
          "id": 3,
          "text": "Heterosexual, transplacental, homosexual"
        },
        {
          "id": 4,
          "text": "Heterosexual, homosexual, transplacental"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The <strong>most common</strong> mode of transmission of HIV in India is <strong>heterosexual</strong>&nbsp;transmission, followed by<strong>&nbsp;transplacental</strong>&nbsp;and<strong>&nbsp;homosexual&nbsp;</strong>contact, respectively.</p>\n<p>The common modes of transmission of HIV are:</p>\n<ul>\n<li aria-level=\"1\">Heterosexual (83.7%)</li>\n<li aria-level=\"1\">Injecting drug users (5.6%)</li>\n<li aria-level=\"1\">Transplacental transmission (3.8 %)</li>\n<li aria-level=\"1\">Homosexual (2.5%)</li>\n<li aria-level=\"1\">Blood and blood products (0.8%)</li>\n<li aria-level=\"1\">Unknown (3.6%)</li>\n</ul>\n<p>The<strong> highest risk</strong> <strong>of transmission</strong> is seen in <strong>homosexuals</strong> due to the increased risk of abrasions during anal sex.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8145",
      "difficulty": "medium"
    },
    {
      "text": "Health care workers will require post-exposure prophylaxis after exposure to which of the following body fluids of an HIV patient?",
      "choices": [
        {
          "id": 1,
          "text": "Tears"
        },
        {
          "id": 2,
          "text": "Urine"
        },
        {
          "id": 3,
          "text": "Saliva"
        },
        {
          "id": 4,
          "text": "Menstrual blood"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Health care workers exposed&nbsp;to the&nbsp;<strong>menstrual blood</strong> of an HIV-positive patient will require <strong>post-exposure prophylaxis</strong>. The risk of transmission of HIV during vaginal intercourse is higher when the woman is menstruating.</p>\n<p>Tears, non-blood-stained saliva, urine, and sweat do not pose a significant risk. Exposure to these fluids does not require post-exposure prophylaxis.</p><p><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;WHO recommends the dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection. The ring works by releasing the antiretroviral drug dapivirine into the vagina slowly over 28 days.&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:61,&quot;3&quot;:{&quot;1&quot;:0},&quot;5&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;6&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;7&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;8&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]}}\">WHO recommends the <strong>dapivirine</strong> <strong>vaginal ring</strong> as a new choice for HIV prevention in high-risk women as part of combination prevention approaches.&nbsp;The ring works by releasing the antiretroviral drug dapivirine into the vagina slowly over 28 days.</span></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4986",
      "difficulty": "easy"
    },
    {
      "text": "As per WHO staging of HIV, which of the following HIV-positive patients cannot be classified as stage IV?",
      "choices": [
        {
          "id": 1,
          "text": "A 29-year-old man diagnosed with cerebral toxoplasmosis"
        },
        {
          "id": 2,
          "text": "A 56-year-old woman with significant weight loss and muscle wasting"
        },
        {
          "id": 3,
          "text": "A 43-year-old lady being treated for Pneumocystis pneumonia"
        },
        {
          "id": 4,
          "text": "A 32-year-old man with oral candidiasis"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Oral candidiasis</strong> is seen in <strong>stage 3,</strong> not stage 4 of HIV.</p>\n<p>The following conditions are included in the WHO stage IV of HIV:</p>\n<ul>\n<li><strong>HIV wasting syndrome</strong> (Slim disease)</li>\n<li>HIV encephalopathy</li>\n<li>HIV-associated nephropathy or cardiomyopathy</li>\n<li>Infections:\n<ul>\n<li><strong><em>Pneumocystis jiroveci</em> pneumonia</strong> (previously known as <em>Pneumocystis carinii</em>)</li>\n<li>Chronic herpes simplex infection, cytomegalovirus disease</li>\n<li><strong>Oesophageal/ tracheal candidiasis&nbsp;</strong></li>\n<li>Extrapulmonary TB or&nbsp;disseminated <em>M. avium</em> infection</li>\n<li><strong>CNS toxoplasmosis</strong></li>\n<li>Extrapulmonary cryptococcosis</li>\n<li>Chronic cryptosporidiosis or&nbsp;isosporiasis</li>\n<li>Disseminated fungal infections (histoplasmosis, coccidioidomycosis)</li>\n<li>Recurrent severe bacterial pneumonia or&nbsp;septicemia&nbsp;</li>\n<li>Atypical disseminated leishmaniasis</li>\n<li>Progressive multifocal leukoencephalopathy</li>\n</ul>\n</li>\n<li>Neoplasms:\n<ul>\n<li>Kaposi sarcoma</li>\n<li>Lymphoma (cerebral or B cell non-Hodgkin)</li>\n<li>Invasive cervical carcinoma</li>\n</ul>\n</li>\n</ul><hr><h3>Related Pearl: WHO clinical staging of HIV</h3><table>\n<tbody>\n<tr>\n<td><strong>Selected conditions &amp; respective clinical stages in HIV &nbsp;</strong></td>\n</tr>\n<tr>\n<td><strong>Clinical stage 1</strong>\n<ul>\n<li>Asymptomatic</li>\n<li>Persistent generalized lymphadenopathy</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Clinical stage 2 (Mild Symptoms)</strong>\n<ul>\n<li>Moderate unexplained weight loss (&lt;10% ofpresumed or measured body weight)&nbsp;</li>\n<li>Recurrent respiratory tract infections (sinusitis,tonsillitis, otitis media, pharyngitis)&nbsp;</li>\n<li>Herpes zoster&nbsp; &nbsp; &nbsp; &nbsp;</li>\n<li>Angular cheilitis&nbsp; &nbsp; &nbsp; &nbsp;</li>\n<li>Recurrent oral ulceration&nbsp; &nbsp; &nbsp; &nbsp;</li>\n<li>Papular pruritic eruption&nbsp; &nbsp; &nbsp; &nbsp;</li>\n<li>Fungal nail infections&nbsp; &nbsp; &nbsp; &nbsp;</li>\n<li>Seborrhoeic dermatitis&nbsp; &nbsp; &nbsp; &nbsp;</li>\n<li>Unexplained persistent hepatosplenomegaly*&nbsp; &nbsp; &nbsp; &nbsp;</li>\n<li>Extensive wart virus infection*&nbsp; &nbsp; &nbsp; &nbsp;</li>\n<li>Extensive molluscum contagiosum*&nbsp; &nbsp; &nbsp; &nbsp;</li>\n<li>Unexplained persistent parotid enlargement*</li>\n</ul>\n<p>&nbsp;*In Children</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Clinical stage 3 &amp; 4 represent Advanced &amp; Severe illness respectively</strong></p>\n<p>For complete staging, please refer WHO guidelines.</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8155",
      "difficulty": "medium"
    },
    {
      "text": "A 45-year man with a high-risk sexual history now presents with prolonged fever for the past 1.5 months. On examination, the following finding is noted. Which one of the following additional features is required to diagnose this patient with AIDS?",
      "choices": [
        {
          "id": 1,
          "text": "Generalised lymphadenopathy > 1 month"
        },
        {
          "id": 2,
          "text": "Generalized pruritic dermatitis"
        },
        {
          "id": 3,
          "text": "Chronic diarrhea > 1 month"
        },
        {
          "id": 4,
          "text": "Persistent cough > 1 month"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>This clinical scenario is suspicious for HIV infection. As per the WHO definition, the presence of&nbsp;<strong>chronic diarrhea &gt; 1 month</strong> is needed to diagnose this patient with <strong>AIDS</strong>.</p>\n<p>The WHO clinical definition is used for&nbsp;<strong>AIDS</strong> <strong>surveillance</strong> in the clinical setting. Patients <strong>&gt; 12 years</strong> of age are said to have AIDS if they have at least <strong>2 major&nbsp;</strong>and <strong>1 minor</strong>&nbsp;signs, provided other clinically similar conditions are be ruled out.</p>\n<p>Major signs:</p>\n<ul>\n<li>Weight loss &ge; 10% of body weight</li>\n<li>Chronic diarrhea &gt; 1 month</li>\n<li>Prolonged fever for &gt; 1 month (intermittent or constant)</li>\n</ul>\n<p>Minor signs:</p>\n<ul>\n<li>A persistent cough &gt; 1 month</li>\n<li>Generalized pruritic dermatitis</li>\n<li>History of herpes zoster</li>\n<li>Oropharyngeal candidiasis</li>\n<li>Chronic progressive or disseminated herpes simplex infection</li>\n<li>Generalized lymphadenopathy</li>\n</ul>\n<p>For surveillance purposes, the presence of either of the following is also considered <strong>sufficient to diagnose</strong> AIDS:</p>\n<ul>\n<li>Generalized <strong>Kaposi's sarcoma</strong></li>\n<li><strong>Cryptococcal meningitis</strong>&nbsp;</li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/a588ac7ccf234a548be050abda55c81e.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8157",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is incorrect regarding the epidemiology of HIV?",
      "choices": [
        {
          "id": 1,
          "text": "HIV infected infants and children do not progress rapidly to AIDS"
        },
        {
          "id": 2,
          "text": "Seminal secretions are more infectious than vaginal secretion"
        },
        {
          "id": 3,
          "text": "People are infectious during the window period"
        },
        {
          "id": 4,
          "text": "HIV prevalence has not exceeded 5% in any subpopulation"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Infants </strong>and<strong> children </strong>infected with HIV<strong> progress rapidly </strong>to<strong> AIDS.&nbsp;</strong></p>\n<p><strong>Semen</strong> is <strong>more infectious</strong> than vaginal or cervical fluids as it has a higher concentration of HIV.</p>\n<p>HIV-infected patients are <strong>highly infectious</strong> during:</p>\n<ul>\n<li><strong>Window period</strong> (very early stages before antibody production)&nbsp;</li>\n<li>Advanced stages of infection (due to higher levels of viremia)&nbsp;</li>\n</ul>\n<p><strong>&nbsp;HIV prevalence</strong> has consistently remained &lt; <strong>5%</strong> in all defined subpopulations.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8163",
      "difficulty": "hard"
    },
    {
      "text": "In individuals exposed to HIV, within how many hours should prophylaxis be initiated?",
      "choices": [
        {
          "id": 1,
          "text": "6 hours"
        },
        {
          "id": 2,
          "text": "24 hours"
        },
        {
          "id": 3,
          "text": "48 hours"
        },
        {
          "id": 4,
          "text": "72 hours"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Post-exposure prophylaxis</strong> for HIV should ideally be initiated <strong>within 72 hours.</strong>&nbsp;It is recommended that it be started as even as early as &lt; 2 hours.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8172",
      "difficulty": "medium"
    },
    {
      "text": "A nurse sustained a needle stick injury while sampling the blood of a patient who is HIV-positive. Which of the following is incorrect?",
      "choices": [
        {
          "id": 1,
          "text": "Washing hands with soap and water"
        },
        {
          "id": 2,
          "text": "Administration of tenofovir monotherapy"
        },
        {
          "id": 3,
          "text": "Measure baseline viral markers of health care worker immediately"
        },
        {
          "id": 4,
          "text": "Measure viral markers after 6 weeks"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Triple therapy</strong>&nbsp;(<strong>tenofovir </strong>300mg +&nbsp;<strong>lamivudine </strong>300mg&nbsp;+ <strong>dolutegravir </strong>50mg) is recommended for <strong>HIV</strong> post-exposure prophylaxis (<strong>PEP</strong>), not monotherapy.&nbsp;</p>\n<p>Steps to be undertaken after a needlestick injury are:</p>\n<ul>\n<li>Wash the wound and skin with water and soap. Do not scrub and avoid antiseptics.</li>\n<li>Assess exposed individual:\n<ul>\n<li>Check <strong>baseline viral markers</strong></li>\n<li>Monitor for <strong>acute seroconversion</strong> illness within<strong> 3-6 weeks</strong> after exposure</li>\n<li>If testing is positive, refer to ART center&nbsp;</li>\n</ul>\n</li>\n<li>Assess exposure source and determine the risk of transmission&nbsp;</li>\n<li>Counseling and support</li>\n<li>Initiate <strong>PEP</strong> at the earliest - preferably &lt; 2 hours and ideally <strong>&lt; 72 hours</strong></li>\n<li><strong>28-day prescription</strong> with drug information</li>\n<li>HIV test at 3 months after exposure</li>\n</ul><hr><h3>Related Pearl: WHO 2018 guidelines for post exposure prophylaxis regimen in HIV</h3><div class=\"page\" title=\"Page 39\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>An HIV post-exposure prophylaxis regimen with two ARV drugs is effective, but three drugs are preferred.</p>\n<p>The recent MOHFW January 2020 guidelines on the management of PEP in HIV recommends the replacement of 2 drug regimen with 3 drug regimen referring to WHO December 2018 guidelines on PEP management protocol in HIV. This shift towards recommending a three-drug regimen for<br />everyone was based on the availability of less toxic and better-tolerated medications.</p>\n<div class=\"page\" title=\"Page 39\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>ADULTS AND ADOLESCENTS:-</strong></p>\n<p>Preferred backbone regimen -&nbsp;TDF + 3TC (or FTC)</p>\n<p>New drug - &nbsp;DTG is the preferred third drug for HIV post-exposure prophylaxis</p>\n<p>New drug -&nbsp;<span>ATV/r, DRV/r, LPV/r and RAL may be considered as alternative third drug options for post-exposure prophylaxis</span></p>\n<p><strong>CHILDREN:-</strong></p>\n<div class=\"page\" title=\"Page 39\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Preferred backbone regimen -&nbsp;AZT + 3TC</p>\n<div class=\"page\" title=\"Page 39\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>ABC + 3TC or TDF + 3TC (or FTC) can be considered as alternative regimens</p>\n<p>New drug -&nbsp;DTG is the preferred third drug for HIV post-exposure prophylaxis</p>\n<p>New drug -&nbsp;<span>ATV/r, DRV/r, LPV/r and RAL may be considered as alternative third drug options for post-exposure prophylaxis</span></p>\n<p>&nbsp;</p>\n<p><span>Legend</span></p>\n<p><span>TDF - Tenofovir disoproxil fumarate&nbsp;</span></p>\n<p>3TC - Lamivudine&nbsp;</p>\n<p>FTC - Emtricitabine&nbsp;</p>\n<p>DTG - Dolutegravir&nbsp;</p>\n<p>ATV/r - Atazanavir + ritonavir&nbsp;</p>\n<p>DRV/r - Darunavir + ritonavir&nbsp;</p>\n<p>LPV/r - Lopinavir + ritonavir&nbsp;</p>\n<p>RAL - Raltegravir&nbsp;</p>\n<p>AZT - Zidovudine&nbsp;</p>\n<p>ABC - Abacavir&nbsp;</p>\n<p>&nbsp;</p>\n</div>\n</div>\n</div>\n<div class=\"page\" title=\"Page 39\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>&nbsp;</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n<p>&nbsp;</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div><hr><h3>Related Pearl: 2021 NACO Guidelines on Post-exposure Prophylaxis (PEP) for HIV</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Exposure Code</strong></p>\n</td>\n<td>\n<p><strong>HIV Source Code</strong></p>\n</td>\n<td>\n<p><strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; PEP Recommendation</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>1</p>\n</td>\n<td>\n<p>&nbsp;1</p>\n</td>\n<td>\n<p>&nbsp;Not required</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>1</p>\n</td>\n<td>\n<p>&nbsp;2</p>\n</td>\n<td>\n<p>&nbsp;Recommended</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>2</p>\n</td>\n<td>\n<p>&nbsp;1</p>\n</td>\n<td>\n<p>&nbsp;Recommended</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>2</p>\n</td>\n<td>\n<p>&nbsp;2</p>\n</td>\n<td>\n<p>&nbsp;Recommended</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>3</p>\n</td>\n<td>\n<p>&nbsp;1/2</p>\n</td>\n<td>\n<p>&nbsp;Recommended</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>2/3</p>\n</td>\n<td>\n<p>Not known</p>\n</td>\n<td>\n<p>Consider PEP if HIV prevalence is high in the given population</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\">\n<p><strong>Exposure Codes</strong></p>\n<ul>\n<li>EC1: <strong>Mild exposure:</strong> mucous membrane/non-intact skin with small volumes/eyes or mucous membrane or subcutaneous injections following small-bore needles</li>\n<li>EC2:&nbsp;<strong>Moderate exposure: </strong>mucous membrane/non-intact skin with large volumes or percutaneous superficial exposure with a solid needle</li>\n<li>EC3:&nbsp;<strong>Severe exposure: </strong>percutaneous with large volume by hollow needle, deep puncture</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\">\n<p><strong>HIV Source Codes</strong></p>\n<ul>\n<li>SC 1- HIV +ve, asymptomatic, CD count high, low viral load</li>\n<li>SC 2- HIV +ve, symptomatic, CD count low, high viral load</li>\n<li>SC unknown: HIV status unknown</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\">\n<p><strong>Recommended PEP regimens</strong></p>\n<p>1) <strong>Adolescents and Adults</strong> (&gt;10 years of age and &gt;30 kg weight): Tenofovir 300 mg + Lamivudine 300 mg + Dolutegravir 50 mg</p>\n<p>2) <strong>Children&nbsp;</strong>(&gt;6 years of age and &gt;20 kg weight): Zidovudine&nbsp;(dosage as per weight band) + Lamivudine (dosage as per weight band) + Dolutegravir 50 mg</p>\n<ul>\n<li aria-level=\"1\">PEP must be initiated ideally <strong>within 2 hours</strong> and certainly within 72 hours.</li>\n<li aria-level=\"1\">Duration of PEP: <strong>28 days/4weeks</strong></li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0176",
      "difficulty": "medium"
    },
    {
      "text": "A resident doctor sustained a needlestick injury while sampling blood of a patient who is HIV positive. A decision is taken to offer him post-exposure prophylaxis. Which one of the following would be the best recommendation?",
      "choices": [
        {
          "id": 1,
          "text": "Zidovudine + Lamivudine for 4 weeks"
        },
        {
          "id": 2,
          "text": "Lamivudine + Tenofovir + Efavirenz for 4 weeks"
        },
        {
          "id": 3,
          "text": "Lamivudine + Tenofovir  + Dolutegravir for 4 weeks"
        },
        {
          "id": 4,
          "text": "Zidovudine + Lamivudine + Nevirapine for 4 weeks"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Triple therapy</strong>&nbsp;with&nbsp;<strong>tenofovir </strong>300mg,&nbsp;<strong>lamivudine </strong>300mg, and&nbsp;<strong>dolutegravir </strong>50mg for 4 weeks is recommended for <strong>HIV</strong> post-exposure prophylaxis (<strong>PEP</strong>).</p>\n<p>Steps to be undertaken after a needlestick injury are:</p>\n<ul>\n<li>Wash the wound and skin with water and soap. Do not scrub and avoid antiseptics.</li>\n<li>Assess exposed individual:\n<ul>\n<li>Check <strong>baseline viral markers</strong></li>\n<li>Monitor for <strong>acute seroconversion</strong> illness within<strong> 3-6 weeks</strong> after exposure</li>\n<li>If testing is positive, refer to ART center&nbsp;</li>\n</ul>\n</li>\n<li>Assess exposure source and determine the risk of transmission&nbsp;</li>\n<li>Counseling and support</li>\n<li>Initiate <strong>PEP</strong> at the earliest - preferably &lt; 2 hours and ideally <strong>&lt; 72 hours</strong></li>\n<li><strong>28-day prescription</strong> with drug information</li>\n<li>HIV test at 3 months after exposure</li>\n</ul><hr><h3>Related Pearl: WHO 2018 guidelines for post exposure prophylaxis regimen in HIV</h3><div class=\"page\" title=\"Page 39\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>An HIV post-exposure prophylaxis regimen with two ARV drugs is effective, but three drugs are preferred.</p>\n<p>The recent MOHFW January 2020 guidelines on the management of PEP in HIV recommends the replacement of 2 drug regimen with 3 drug regimen referring to WHO December 2018 guidelines on PEP management protocol in HIV. This shift towards recommending a three-drug regimen for<br />everyone was based on the availability of less toxic and better-tolerated medications.</p>\n<div class=\"page\" title=\"Page 39\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>ADULTS AND ADOLESCENTS:-</strong></p>\n<p>Preferred backbone regimen -&nbsp;TDF + 3TC (or FTC)</p>\n<p>New drug - &nbsp;DTG is the preferred third drug for HIV post-exposure prophylaxis</p>\n<p>New drug -&nbsp;<span>ATV/r, DRV/r, LPV/r and RAL may be considered as alternative third drug options for post-exposure prophylaxis</span></p>\n<p><strong>CHILDREN:-</strong></p>\n<div class=\"page\" title=\"Page 39\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Preferred backbone regimen -&nbsp;AZT + 3TC</p>\n<div class=\"page\" title=\"Page 39\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>ABC + 3TC or TDF + 3TC (or FTC) can be considered as alternative regimens</p>\n<p>New drug -&nbsp;DTG is the preferred third drug for HIV post-exposure prophylaxis</p>\n<p>New drug -&nbsp;<span>ATV/r, DRV/r, LPV/r and RAL may be considered as alternative third drug options for post-exposure prophylaxis</span></p>\n<p>&nbsp;</p>\n<p><span>Legend</span></p>\n<p><span>TDF - Tenofovir disoproxil fumarate&nbsp;</span></p>\n<p>3TC - Lamivudine&nbsp;</p>\n<p>FTC - Emtricitabine&nbsp;</p>\n<p>DTG - Dolutegravir&nbsp;</p>\n<p>ATV/r - Atazanavir + ritonavir&nbsp;</p>\n<p>DRV/r - Darunavir + ritonavir&nbsp;</p>\n<p>LPV/r - Lopinavir + ritonavir&nbsp;</p>\n<p>RAL - Raltegravir&nbsp;</p>\n<p>AZT - Zidovudine&nbsp;</p>\n<p>ABC - Abacavir&nbsp;</p>\n<p>&nbsp;</p>\n</div>\n</div>\n</div>\n<div class=\"page\" title=\"Page 39\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>&nbsp;</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n<p>&nbsp;</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div><hr><h3>Related Pearl: 2021 NACO Guidelines on Post-exposure Prophylaxis (PEP) for HIV</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Exposure Code</strong></p>\n</td>\n<td>\n<p><strong>HIV Source Code</strong></p>\n</td>\n<td>\n<p><strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; PEP Recommendation</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>1</p>\n</td>\n<td>\n<p>&nbsp;1</p>\n</td>\n<td>\n<p>&nbsp;Not required</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>1</p>\n</td>\n<td>\n<p>&nbsp;2</p>\n</td>\n<td>\n<p>&nbsp;Recommended</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>2</p>\n</td>\n<td>\n<p>&nbsp;1</p>\n</td>\n<td>\n<p>&nbsp;Recommended</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>2</p>\n</td>\n<td>\n<p>&nbsp;2</p>\n</td>\n<td>\n<p>&nbsp;Recommended</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>3</p>\n</td>\n<td>\n<p>&nbsp;1/2</p>\n</td>\n<td>\n<p>&nbsp;Recommended</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>2/3</p>\n</td>\n<td>\n<p>Not known</p>\n</td>\n<td>\n<p>Consider PEP if HIV prevalence is high in the given population</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\">\n<p><strong>Exposure Codes</strong></p>\n<ul>\n<li>EC1: <strong>Mild exposure:</strong> mucous membrane/non-intact skin with small volumes/eyes or mucous membrane or subcutaneous injections following small-bore needles</li>\n<li>EC2:&nbsp;<strong>Moderate exposure: </strong>mucous membrane/non-intact skin with large volumes or percutaneous superficial exposure with a solid needle</li>\n<li>EC3:&nbsp;<strong>Severe exposure: </strong>percutaneous with large volume by hollow needle, deep puncture</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\">\n<p><strong>HIV Source Codes</strong></p>\n<ul>\n<li>SC 1- HIV +ve, asymptomatic, CD count high, low viral load</li>\n<li>SC 2- HIV +ve, symptomatic, CD count low, high viral load</li>\n<li>SC unknown: HIV status unknown</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\">\n<p><strong>Recommended PEP regimens</strong></p>\n<p>1) <strong>Adolescents and Adults</strong> (&gt;10 years of age and &gt;30 kg weight): Tenofovir 300 mg + Lamivudine 300 mg + Dolutegravir 50 mg</p>\n<p>2) <strong>Children&nbsp;</strong>(&gt;6 years of age and &gt;20 kg weight): Zidovudine&nbsp;(dosage as per weight band) + Lamivudine (dosage as per weight band) + Dolutegravir 50 mg</p>\n<ul>\n<li aria-level=\"1\">PEP must be initiated ideally <strong>within 2 hours</strong> and certainly within 72 hours.</li>\n<li aria-level=\"1\">Duration of PEP: <strong>28 days/4weeks</strong></li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9547",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following HIV-infected patients would you start on cotrimoxazole prophylaxis?",
      "choices": [
        {
          "id": 1,
          "text": "A 24-year-old pregnant woman with WHO stage 2 disease."
        },
        {
          "id": 2,
          "text": "A 47-year-old man in a malaria-endemic area with WHO stage 1 disease"
        },
        {
          "id": 3,
          "text": "A 2-week-old HIV-exposed infant who is being exclusively breastfed"
        },
        {
          "id": 4,
          "text": "A 7-year-old girl with a CD4 count of 400 cells/cubic mm"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>All HIV infected <strong>adults and children</strong> in <strong>malaria-endemic</strong> areas should be given <strong>cotrimoxazole prophylaxis</strong> regardless of CD4 count or WHO clinical stage.</p>\n<p>Cotrimoxazole is also indicated in areas with a <strong>low prevalence of malaria</strong> as shown below:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Age group</strong></td>\n<td><strong>Indication</strong></td>\n<td><strong>When to discontinue</strong></td>\n</tr>\n<tr>\n<td>HIV-exposed infants &gt; 4-6 weeks of age</td>\n<td>All infants</td>\n<td>After HIV infection has been ruled out</td>\n</tr>\n<tr>\n<td>Children &lt; 5 years</td>\n<td>All children</td>\n<td>\n<p>At 5 years in areas with low prevalence of malaria </p>\n<p>(In high prevalence areas, continue till adulthood)</p>\n</td>\n</tr>\n<tr>\n<td>Children &gt; 5 years</td>\n<td>CD4 count &lt;350 and/or WHO stage 3/4</td>\n<td>When CD4 &gt; 350 and they have been on ART &gt; 6 months</td>\n</tr>\n<tr>\n<td>Adults and pregnant women</td>\n<td>CD4 count &lt;350 and/or WHO stage 3/4</td>\n<td>When CD4 count is rising and viral load is decreasing</td>\n</tr>\n<tr>\n<td>HIV and TB coinfection </td>\n<td>All patients</td>\n<td>—</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4989",
      "difficulty": "hard"
    },
    {
      "text": "A 45-year-old man with HIV is being screened for symptoms of TB. He reports no cough, fever, night sweats, or weight loss. What is the next step in management?",
      "choices": [
        {
          "id": 1,
          "text": "Start 5 mg/kg/day Isoniazid daily for 9 months"
        },
        {
          "id": 2,
          "text": "Prophylaxis does not need to be started"
        },
        {
          "id": 3,
          "text": "Rifabutin prophylaxis should be started"
        },
        {
          "id": 4,
          "text": "Start weekly dose of rifapentine + isoniazid for 3 months"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The next step in management in this patient is to provide&nbsp;<strong>tuberculosis preventive therapy</strong>&nbsp;(TPT) with <strong>rifapentine+ isoniazid weekly</strong>&nbsp;for <strong>3&nbsp;months</strong>.</p>\n<p>According to the NTEP guidelines, TPT is indicated for the following groups:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>&nbsp; &nbsp; &nbsp; Risk group</strong></td>\n<td><strong>&nbsp; &nbsp; &nbsp; Criteria&nbsp;</strong></td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>People living with HIV</li>\n</ul>\n</td>\n<td>\n<ul>\n<li aria-level=\"1\">Negative 4 symptom test - start TPT after ruling out TB</li>\n<li aria-level=\"1\">Patients with active TB - start TPT after completion of the ATT regimen</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Household contacts (HHC) of pulmonary TB patients &nbsp;&lt; 5 years</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>Start TPT after ruling out active TB</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Household contacts of pulmonary TB patients &nbsp;&ge; 5 years</li>\n<li>Other risk groups:</li>\n<li>Children/adults on immunosuppressive therapy</li>\n<li>Patients on anti-TNF treatment</li>\n<li>Patients on dialysis or post-transplantation</li>\n<li>Patients with silicosis</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>First rule out active TB</li>\n<li>Start TPT if <strong>IGRA or TST</strong> is <strong>positive</strong> with a normal chest x-ray</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>IGRA - interferon-gamma release assay; TST - tuberculin skin test; ATT - antituberculous therapy</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Target Population</strong></td>\n<td><strong>Treatment option</strong></td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>People living with HIV (adults and children &gt; 2 years)</li>\n</ul>\n<ul>\n<li>HHC of pulmonary TB patients</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>3-month weekly Isoniazid (300 mg) and Rifapentine (300 mg) in persons older than 2 years</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Infants &lt;12 months of age and Children &lt; 2years of age with HIV</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>6-months daily isoniazid (6H): 10 mg/kg/day</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>TPT is <strong>contraindicated</strong> under the following conditions:</p>\n<ul>\n<li aria-level=\"1\">Active TB</li>\n<li aria-level=\"1\">Active hepatitis</li>\n<li aria-level=\"1\">Peripheral neuropathy</li>\n<li aria-level=\"1\">Regular and heavy alcohol consumption</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4992",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is true about the 2025 targets of the Global AIDS Strategy for 2021 to 2026?<div class='question-desc-html'><p>A. 95% of women of reproductive age must have their HIV and reproductive health needs met<br />B. 95% of pregnant/ breastfeeding women with HIV must have suppressed viral loads<br />C. 75% of HIV-exposed children must be tested at 2 months of age and after stopping breastfeeding<br />D. 90% of people living with HIV must receive preventive treatment for TB<br />E. 75% of children living with HIV must have suppressed viral loads by 2023</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "B,E only"
        },
        {
          "id": 2,
          "text": "A,B,C only"
        },
        {
          "id": 3,
          "text": "A,B,D,E only"
        },
        {
          "id": 4,
          "text": "C,D only"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>95%</strong>, not 75% of<strong> HIV-exposed children</strong> are tested by <strong>2 months</strong> of age and after <strong>stopping breastfeeding</strong> according to the 2025 targets.</p>\n<p>Global AIDS Strategy 2021-2026 has the following targets for the year 2025:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Target %</strong></td>\n<td><strong>Target population</strong></td>\n<td><strong>Target intervention</strong></td>\n</tr>\n<tr>\n<td>95% of</td>\n<td>People at risk of HIV infection</td>\n<td>Access to effective <strong>prevention</strong> <strong>options</strong></td>\n</tr>\n<tr>\n<td>&nbsp;</td>\n<td>Women of reproductive age</td>\n<td>Have their HIV, sexual, reproductive <strong>health service needs</strong> met</td>\n</tr>\n<tr>\n<td>&nbsp;</td>\n<td>Pregnant and breastfeeding women with HIV</td>\n<td>Suppressed <strong>viral loads</strong></td>\n</tr>\n<tr>\n<td>&nbsp;</td>\n<td>HIV-exposed children</td>\n<td>Tested by 2 months of age and again after stopping breastfeeding</td>\n</tr>\n<tr>\n<td>90% of</td>\n<td>People living with HIV</td>\n<td>Preventive treatment for <strong>TB</strong></td>\n</tr>\n<tr>\n<td>&nbsp;</td>\n<td>People living with HIV and people at risk</td>\n<td>\n<p>Linked to services for overall health and wellbeing including:</p>\n<ul>\n<li>Communicable and non-communicable diseases</li>\n<li>Sexual health</li>\n<li>Gender-based violence</li>\n<li>Mental health and substance abuse</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>75% of</td>\n<td>All children living with HIV</td>\n<td>Suppressed<strong> viral loads</strong> by 2023 (interim target)</td>\n</tr>\n<tr>\n<td colspan=\"3\"><strong>95&ndash;95&ndash;95</strong> testing and treatment targets to be achieved within all subpopulations, age groups, and geographic settings, including children living with HIV.</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC5818",
      "difficulty": "medium"
    },
    {
      "text": "A 29-year-old man comes to you with complaints of painful swelling in his right groin, as shown below. He gives a history of 3-4 painless ulcers over his penis 4 weeks ago that had resolved on its own. What is the likely causative organism?",
      "choices": [
        {
          "id": 1,
          "text": "Haemophilus ducreyi"
        },
        {
          "id": 2,
          "text": "Calymmotabacterium granulomatis"
        },
        {
          "id": 3,
          "text": "Treponema pallidum"
        },
        {
          "id": 4,
          "text": "Chlamydia trachomatis"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>This clinical scenario and image showing the<strong> groove sign</strong> of Greenblatt are suggestive of&nbsp;lymphogranuloma venereum<strong>&nbsp;</strong>(<strong>LGV</strong>). The causative organism is <em><strong>Chlamydia trachomatis.</strong></em>&nbsp;</p>\n<p>LGV commonly presents with multiple <strong>small, painless ulcers</strong> on the genitalia that are often unrecognized and resolve spontaneously. This is followed by<strong> painful lymphadenopathy</strong> and <strong>bubo</strong> formation after 4-6 weeks. If left untreated, it can lead to extensive lymphatic damage, elephantiasis, and deformity of the genitalia.</p>\n<p>The treatment of choice is <strong>doxycycline</strong>.</p><hr><h3>Related Pearl: Important sexually transmitted pathogens and the diseases caused by them</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Pathogen </strong></p>\n</td>\n<td>\n<p><strong>Disease or syndrome </strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Neisseria gonorrhoeae</p>\n</td>\n<td>\n<p>Gonorrhea, urethritis, cervicitis, epididymitis, salpingitis, PID, neonatal conjunctivitis</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Treponema pallidum</p>\n</td>\n<td>\n<p>Syphillis</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Haemophilus ducreyi</p>\n</td>\n<td>\n<p>Chancroid</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Chlamydia trachomatis</p>\n</td>\n<td>\n<p>LGV, urethritis, cervicitis, proctitis, epididymis, infant pneumonia, Reiter's syndrome, PID, neonatal conjunctivitis</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Klebsiella granulomatis (prev called Calymmatobacterium)</p>\n</td>\n<td>\n<p>Donovanosis (granuloma inguinale)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Herpes simplex virus</p>\n</td>\n<td>\n<p>Genital herpes</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hepatitis B virus</p>\n</td>\n<td>\n<p>Acute and chronic hepatitis&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Human papillomaviruses&nbsp;</p>\n</td>\n<td>\n<p>Genital and anal warts</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>HIV</p>\n</td>\n<td>\n<p>AIDS</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Molluscum contagiosum</p>\n</td>\n<td>\n<p>Genital molluscum contagiosum</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Candida albicans</p>\n</td>\n<td>\n<p>Vaginitis</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Trichomonas vaginalis</p>\n</td>\n<td>\n<p>Vaginitis</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Comparison of Genital Ulcers</h3><table>\n<tbody>\n<tr>\n<td><span>&nbsp;</span></td>\n<td><span><strong>Genital herpes</strong></span></td>\n<td><span><strong>&nbsp;Syphilitic chancre (Hard chancre)</strong></span></td>\n<td><span><strong>Donovanosis/ granuloma inguinale</strong></span></td>\n<td><span><strong>Chancroid (soft chancre)</strong></span></td>\n<td><span><strong>LGV</strong></span></td>\n</tr>\n<tr>\n<td><span><strong>Incubation period</strong></span></td>\n<td><span>2-7 days</span></td>\n<td>\n<p><span>10-90 days&nbsp;</span></p>\n<p><span>Average: 21days</span></p>\n</td>\n<td><span>1-12 weeks</span></td>\n<td><span>1-14 days</span></td>\n<td><span>3 days - 6 weeks</span></td>\n</tr>\n<tr>\n<td><span><strong>Causative agent</strong></span></td>\n<td><span>HSV-2&gt;HSV-1</span></td>\n<td><em><span>Treponema pallidum</span></em></td>\n<td><em><span>Klebsiella granulomatis</span></em></td>\n<td><em><span>Hemophilus ducreyi</span></em></td>\n<td>\n<p><span><em>Chlamydia trachomatis</em></span><span>&nbsp;serovars L1,L2,L3</span></p>\n</td>\n</tr>\n<tr>\n<td><span><strong>Clinical presentation</strong></span></td>\n<td>\n<p><span>Cluster of vesicles on erythematous base.</span></p>\n<p><span> Painful and pruritic lymphadenopathy</span></p>\n</td>\n<td>\n<p><span>Single painless ulcer with a clean base and a firm raised border. </span></p>\n<p><span>Painless lymphadenopathy</span></p>\n</td>\n<td>\n<p><span>Painless papule or nodule erodes into beefy red granulomatous ulcer with rolled edges.</span></p>\n<p><span> No lymphadenopathy, pseudobubos are seen</span></p>\n</td>\n<td>\n<p><span>Painful ulcer (ducreyi makes you cry).</span></p>\n<p><span>Painful inguinal lymphadenopathy</span></p>\n</td>\n<td>\n<p><span>Painless genital ulcer.</span></p>\n<p><span>Painful inguinal lymphadenopathy</span></p>\n</td>\n</tr>\n<tr>\n<td><span><strong>Diagnosis&nbsp;</strong></span></td>\n<td><span>Tzanck preparation shows multinucleated giant cells, PCR</span></td>\n<td><span>Clinical diagnosis</span></td>\n<td><span>Donovan bodies on biopsy</span></td>\n<td><span>Clinical diagnosis</span></td>\n<td><span>Nucleic acid amplification tests</span></td>\n</tr>\n<tr>\n<td><span><strong>Treatment</strong></span></td>\n<td><span>Acyclovir/famcyclovir or valacyclovir</span></td>\n<td><span>Penicillin/Ceftriaxone</span></td>\n<td>\n<p><span>Azithromycin/</span><span>Doxycycline</span></p>\n</td>\n<td><span>Azithromycin/ceftriaxone</span></td>\n<td><span>&nbsp;Doxycycline</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/e18f884c2ba243b396718760c4789f25.jpg"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8177",
      "difficulty": "medium"
    },
    {
      "text": "Match the following conditions with their causative agents:<div class='question-desc-html'><table>\n<tbody>\n<tr>\n<td>\n<p>&nbsp; &nbsp;I. Pinta</p>\n</td>\n<td>\n<p>&nbsp; A. <em>Treponema pertenue</em></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>&nbsp; &nbsp;II. Lymphogranuloma venereum &nbsp;&nbsp;</p>\n</td>\n<td>&nbsp; B. <em>Klebsiella granulomatis</em></td>\n</tr>\n<tr>\n<td>\n<p>&nbsp; &nbsp;III. Yaws</p>\n</td>\n<td>&nbsp; C. <em>Chlamydia trachomatis</em></td>\n</tr>\n<tr>\n<td>\n<p>&nbsp; &nbsp;IV. Granuloma inguinale</p>\n</td>\n<td>&nbsp; D. <em>Treponema carateum</em></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div>",
      "choices": [
        {
          "id": 1,
          "text": "I-A, II-B, III-D, IV-C"
        },
        {
          "id": 2,
          "text": "I-B, II-A, III-C, IV-D"
        },
        {
          "id": 3,
          "text": "I-D, II-C, III-A, IV-B"
        },
        {
          "id": 4,
          "text": "I-C, II-D, III-B, IV-A"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The causative organisms of the given conditions are as follows:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Condition</strong></td>\n<td><strong>Organism</strong></td>\n</tr>\n<tr>\n<td>Pinta</td>\n<td><em>Treponema carateum</em></td>\n</tr>\n<tr>\n<td>Lymphogranuloma venereum</td>\n<td><em>Chlamydia trachomatis</em></td>\n</tr>\n<tr>\n<td>Yaws</td>\n<td><em>Treponema pertenue</em></td>\n</tr>\n<tr>\n<td>Granuloma inguinale</td>\n<td><em>Klebsiella granulomatis&nbsp;</em></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><strong>India</strong> is the <strong>first country</strong> in the world to be officially acknowledged as being <strong>yaws-free</strong>. The WHO declared India free of yaws on <strong>5th May 2016</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8180",
      "difficulty": "easy"
    },
    {
      "text": "Match the following STDs with their respective incubation periods:<div class='question-desc-html'><table>\n<tbody>\n<tr>\n<td>\n<p>I. Syphilis &nbsp; &nbsp;</p>\n</td>\n<td>A. 2-3 days</td>\n</tr>\n<tr>\n<td>\n<p>II. Chlamydiasis &nbsp;</p>\n</td>\n<td>B. 3-40 days&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>III. Donovanosis &nbsp;&nbsp;</p>\n</td>\n<td>C. 10-90 days</td>\n</tr>\n<tr>\n<td>\n<p>IV. Chancroid &nbsp; &nbsp;</p>\n</td>\n<td>D. 7-21 days</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div>",
      "choices": [
        {
          "id": 1,
          "text": "I-D, II-B, III-A, IV-C"
        },
        {
          "id": 2,
          "text": "I-A, II-C, III-D, IV-B"
        },
        {
          "id": 3,
          "text": "I-B, II-A, III-C, IV-D"
        },
        {
          "id": 4,
          "text": "I-C, II-D, III-B, IV-A"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The incubation periods of various STDs are as follows:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>STD</strong></td>\n<td><strong>Incubation period</strong></td>\n</tr>\n<tr>\n<td>Syphilis</td>\n<td>10-90 days</td>\n</tr>\n<tr>\n<td>Chlamydiasis</td>\n<td>7-21 days</td>\n</tr>\n<tr>\n<td>Donovanosis</td>\n<td>3-40 days</td>\n</tr>\n<tr>\n<td>Chancroid</td>\n<td>2-3 days</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Comparison of Genital Ulcers</h3><table>\n<tbody>\n<tr>\n<td><span>&nbsp;</span></td>\n<td><span><strong>Genital herpes</strong></span></td>\n<td><span><strong>&nbsp;Syphilitic chancre (Hard chancre)</strong></span></td>\n<td><span><strong>Donovanosis/ granuloma inguinale</strong></span></td>\n<td><span><strong>Chancroid (soft chancre)</strong></span></td>\n<td><span><strong>LGV</strong></span></td>\n</tr>\n<tr>\n<td><span><strong>Incubation period</strong></span></td>\n<td><span>2-7 days</span></td>\n<td>\n<p><span>10-90 days&nbsp;</span></p>\n<p><span>Average: 21days</span></p>\n</td>\n<td><span>1-12 weeks</span></td>\n<td><span>1-14 days</span></td>\n<td><span>3 days - 6 weeks</span></td>\n</tr>\n<tr>\n<td><span><strong>Causative agent</strong></span></td>\n<td><span>HSV-2&gt;HSV-1</span></td>\n<td><em><span>Treponema pallidum</span></em></td>\n<td><em><span>Klebsiella granulomatis</span></em></td>\n<td><em><span>Hemophilus ducreyi</span></em></td>\n<td>\n<p><span><em>Chlamydia trachomatis</em></span><span>&nbsp;serovars L1,L2,L3</span></p>\n</td>\n</tr>\n<tr>\n<td><span><strong>Clinical presentation</strong></span></td>\n<td>\n<p><span>Cluster of vesicles on erythematous base.</span></p>\n<p><span> Painful and pruritic lymphadenopathy</span></p>\n</td>\n<td>\n<p><span>Single painless ulcer with a clean base and a firm raised border. </span></p>\n<p><span>Painless lymphadenopathy</span></p>\n</td>\n<td>\n<p><span>Painless papule or nodule erodes into beefy red granulomatous ulcer with rolled edges.</span></p>\n<p><span> No lymphadenopathy, pseudobubos are seen</span></p>\n</td>\n<td>\n<p><span>Painful ulcer (ducreyi makes you cry).</span></p>\n<p><span>Painful inguinal lymphadenopathy</span></p>\n</td>\n<td>\n<p><span>Painless genital ulcer.</span></p>\n<p><span>Painful inguinal lymphadenopathy</span></p>\n</td>\n</tr>\n<tr>\n<td><span><strong>Diagnosis&nbsp;</strong></span></td>\n<td><span>Tzanck preparation shows multinucleated giant cells, PCR</span></td>\n<td><span>Clinical diagnosis</span></td>\n<td><span>Donovan bodies on biopsy</span></td>\n<td><span>Clinical diagnosis</span></td>\n<td><span>Nucleic acid amplification tests</span></td>\n</tr>\n<tr>\n<td><span><strong>Treatment</strong></span></td>\n<td><span>Acyclovir/famcyclovir or valacyclovir</span></td>\n<td><span>Penicillin/Ceftriaxone</span></td>\n<td>\n<p><span>Azithromycin/</span><span>Doxycycline</span></p>\n</td>\n<td><span>Azithromycin/ceftriaxone</span></td>\n<td><span>&nbsp;Doxycycline</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8188",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is not a part of case detection in STDs?",
      "choices": [
        {
          "id": 1,
          "text": "Screening"
        },
        {
          "id": 2,
          "text": "Contact tracing"
        },
        {
          "id": 3,
          "text": "Cluster testing"
        },
        {
          "id": 4,
          "text": "Notification"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Notification is not part of the <strong>case detection</strong> strategy for <strong>STDs</strong>.&nbsp;Case detection in STDs includes the following:</p>\n<ul>\n<li>Screening</li>\n<li>Contact tracing</li>\n<li>Cluster testing</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8190",
      "difficulty": "medium"
    },
    {
      "text": "A 32-year-old man is diagnosed with syphilis. On probing, he gives you the information of other people in the same sociosexual environment as him. You then refer all these people for testing. What is this method of case detection?",
      "choices": [
        {
          "id": 1,
          "text": "Contact testing"
        },
        {
          "id": 2,
          "text": "High-risk screening"
        },
        {
          "id": 3,
          "text": "Selective screening"
        },
        {
          "id": 4,
          "text": "Cluster testing"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>This method of case detection is known as <strong>cluster testing.</strong></p>\n<p>The methods employed in case detection of STDs are:</p>\n<ul>\n<li aria-level=\"1\"><strong>Screening</strong> - testing of apparently healthy volunteers from the general population for early detection of disease</li>\n<li aria-level=\"1\"><strong>Contact tracing</strong>&nbsp;- technique by which the sexual partners of diagnosed patients are identified, located, investigated, and treated</li>\n<li aria-level=\"1\"><strong>Cluster testing</strong>&nbsp;- patients are asked to name other persons who move in the same socio-sexual environment, who are then tested</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8195",
      "difficulty": "hard"
    },
    {
      "text": "A 29-year-old man with urethral discharge is treated with the grey kit. This treatment is effective for the control of which of the following organisms?",
      "choices": [
        {
          "id": 1,
          "text": "Neisseria gonorrhoeae and Herpes genitalis"
        },
        {
          "id": 2,
          "text": "Chlamydia trachomatis and Herpes genitalis"
        },
        {
          "id": 3,
          "text": "Neisseria gonorrhoeae and Chlamydia trachomatis"
        },
        {
          "id": 4,
          "text": "Neisseria gonorrhoea and Treponema pallidum"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The<strong> grey kit</strong> is effective for the treatment of infections caused by <em><strong>Neisseria gonorrhoeae</strong></em> and <strong><em>Chlamydia trachomatis</em></strong>.</p><hr><h3>Related Pearl: Syndromic Management of Sexually Transmitted Infections</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1167210a9cd6434a905a98bc64668d41x1280x2612.PNG\" alt=\"Pearl Image\"><p>Partner Management when <strong>asymptomatic</strong> is not required for <strong>Gardenella vaginalis, Candida and Herpes infections</strong>.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/60da7b1257d04ca5938ef3340533e6b9x1280x2974.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8183",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is false about the epidemiology of leprosy?",
      "choices": [
        {
          "id": 1,
          "text": "Increased prevalence in childhood indicates that the disease is active and spreading."
        },
        {
          "id": 2,
          "text": "Multibacillary cases are the most infectious in the community"
        },
        {
          "id": 3,
          "text": "Bacterial load is highest in patients with tuberculoid leprosy"
        },
        {
          "id": 4,
          "text": "Seldom may be transmitted by insect vectors"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The <strong>bacterial load</strong> is&nbsp;<strong>highest</strong> in patients with&nbsp;<strong>lepromatous leprosy</strong>. 1 gram of leproma contains as many as 2-7 billion bacilli.</p>\n<p><strong>Multibacillary</strong> <strong>cases</strong> (lepromatous and borderline lepromatous) are the most <strong>important source</strong> of infection in the community.&nbsp;Infection can occur at any age. In general, cases rise to a peak between 10-20 years of age and then fall. In endemic areas, the disease is acquired commonly during <strong>childhood.</strong>&nbsp;A <strong>high prevalence</strong> in this age group indicates that the disease is <strong>active and spreading</strong>.</p>\n<p>The organism may also be transmitted by <strong>insect vectors</strong> or by <strong>tattooing</strong> needles. However, this is not clinically significant.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8197",
      "difficulty": "medium"
    },
    {
      "text": "Elimination of leprosy in India is defined as the prevalence of :",
      "choices": [
        {
          "id": 1,
          "text": "< 1 per 1000"
        },
        {
          "id": 2,
          "text": "< 1 per 10,000"
        },
        {
          "id": 3,
          "text": "< 5 per 1000"
        },
        {
          "id": 4,
          "text": "< 5 per 10,000"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Elimination</strong> of leprosy in India is defined as a prevalence of <strong>&lt; 1 per 10,000.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8204",
      "difficulty": "medium"
    },
    {
      "text": "What is the prevalence of leprosy in India per 10,000?",
      "choices": [
        {
          "id": 1,
          "text": "More than 1"
        },
        {
          "id": 2,
          "text": "0.66"
        },
        {
          "id": 3,
          "text": "0.71"
        },
        {
          "id": 4,
          "text": "0.41"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The <strong>prevalence</strong> of <strong>leprosy</strong> in India is <strong>0.41</strong> per 10,000 as of March 2021.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8206",
      "difficulty": "hard"
    },
    {
      "text": "The Ridley Jopling classification for leprosy uses which of the following parameters?",
      "choices": [
        {
          "id": 1,
          "text": "Clinical, bacteriological, immunological, epidemiological"
        },
        {
          "id": 2,
          "text": "Clinical, bacteriological, immunological, therapeutic"
        },
        {
          "id": 3,
          "text": "Clinical, bacteriological, immunological, histological"
        },
        {
          "id": 4,
          "text": "Clinical , immunological, epidemiological, operational"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The Ridley Jopling classification uses <strong>clinical</strong>, b<strong>acteriological, immunological,&nbsp;</strong>and <strong>histological</strong> parameters.</p><hr><h3>Related Pearl: Characteristics of Ridley Jopling Classification in Leprosy</h3><table>\n<tbody>\n<tr>\n<td> </td>\n<td><strong>TT (Tuberculoid Leprosy)</strong></td>\n<td><strong>BT (Borderline Tuberculoid)</strong></td>\n<td><strong>BB (Borderline)</strong></td>\n<td><strong>BL(Borderline Lepromatous)</strong></td>\n<td><strong>LL (Lepromatous Leprosy)</strong></td>\n</tr>\n<tr>\n<td><strong>Number and Type of lesions</strong></td>\n<td><strong>1-3</strong> <strong>well</strong><br /><strong>defined</strong> hypopigmented macule(s) or plaque(s) with elevated sloping borders '<strong>saucer right side up'</strong> lesion. Asymmetrical distribution.</td>\n<td>\n<p>Hypopigmented macules or plaques, variable in number, up to <strong>10</strong>.</p>\n<p>Occasionally showing fingerlike extensions<br />(<strong>pseudopodia</strong>) or <strong>satellite lesions</strong></p>\n</td>\n<td>\n<p>Hypopigmented macules or plaques with annular, ‘<strong>swiss </strong><strong>cheese’</strong> /inverted saucer/punched out appearance</p>\n<p>Variable in number<br /><strong>(10–30)</strong></p>\n</td>\n<td>\n<p><strong>Numerous</strong> hypopigmented macules, papules, plaques, and some nodules, lesions with <strong>swiss </strong><strong>cheese’</strong> /inverted saucer/punched out appearance <strong>almost symmetrical</strong> in<br />distribution</p>\n</td>\n<td>\n<p>Hypopigmented macules, plaques,<br />and nodular lesions</p>\n<p><strong>Innumerable</strong> lesions<br />showing <strong>perfect  symmetrical </strong>distribution</p>\n</td>\n</tr>\n<tr>\n<td><strong>Size of Lesion</strong></td>\n<td>Variable size,<strong>usually</strong><br /><strong>large</strong></td>\n<td>Variable size, some lesions are large</td>\n<td>Variable</td>\n<td>Variable, usually small</td>\n<td><strong>Small</strong></td>\n</tr>\n<tr>\n<td><strong>Surface of Lesion</strong></td>\n<td><strong>Dry, scaly and infiltrated</strong></td>\n<td>Dry, scaly infiltrated (but less than TT)</td>\n<td>Dry, scaly and slightly shiny</td>\n<td>Shiny (less than LL)</td>\n<td><strong>Shiny</strong></td>\n</tr>\n<tr>\n<td><strong>Sensations</strong></td>\n<td><strong>Absent. </strong></td>\n<td>Markedly diminished</td>\n<td>Moderately diminished</td>\n<td>Slightly diminished</td>\n<td><strong>May be normal</strong></td>\n</tr>\n<tr>\n<td><strong>Peripheral Nerves</strong></td>\n<td>\n<p><strong>Asymmetrical, single nerve</strong><br />enlargement.</p>\n<p>Nerve to patch may<br />be palpable</p>\n</td>\n<td>Asymmetrical enlargement of few nerves</td>\n<td>Asymmetrical involvement of several nerves</td>\n<td><strong>Increasingly symmetric</strong> enlargement of nerves</td>\n<td>\n<p><strong>Symmetrical</strong><br /><strong>involvement</strong> of<br />nerve trunks with<br />‘<strong>glove and stocking</strong><br /><strong>anesthesia’</strong>.</p>\n<p>Nerves may feel normal on<br />palpation or may be<br />thickened.</p>\n</td>\n</tr>\n<tr>\n<td><strong>Hair</strong></td>\n<td><strong>Absent</strong></td>\n<td>Markedly diminished</td>\n<td>Moderately diminished</td>\n<td>Slightly diminished</td>\n<td><strong>Almost normal (initially)</strong></td>\n</tr>\n<tr>\n<td><strong>Bacteriology on Split Skin Smear</strong></td>\n<td><strong>Negative</strong></td>\n<td>Negative or Scanty Bacilli</td>\n<td>Moderate number of AFB present</td>\n<td>Large number of AFB </td>\n<td>Plenty of AFB including <strong>Globi</strong> are seen</td>\n</tr>\n<tr>\n<td><strong>Typical Lepra Reaction</strong></td>\n<td>Type 1</td>\n<td>Type 1</td>\n<td>Type 1/Type 2</td>\n<td>Type 1/Type 2</td>\n<td>Type 2</td>\n</tr>\n<tr>\n<td><strong>Lepromin Reactivity</strong></td>\n<td>\n<p><strong>Strongly Positive</strong></p>\n<p>(+++)</p>\n</td>\n<td>\n<p>Weakly Positive</p>\n<p>(+ or ++)</p>\n</td>\n<td>Negative/ Weakly positive</td>\n<td>Negative</td>\n<td><strong>Negative</strong></td>\n</tr>\n<tr>\n<td><strong>Histopathology</strong></td>\n<td>\n<p><strong>Dermal Tuberculoid granulomas</strong> (arranged around nerves)</p>\n<p><strong>No bacilli are seen</strong></p>\n</td>\n<td>\n<p>Fewer Tuberculoid granulomas</p>\n<p><strong>Grenz clear zone</strong> in upper papillary dermis <strong>starts to form</strong></p>\n<p>Nerves are<br />replaced by granulomas</p>\n<p>Fragmented<br />bacilli are seen with AFB stain</p>\n</td>\n<td>\n<p>Tuberculoid granulomas less prominent</p>\n<p>Grenz zone is more prominent</p>\n<p>Transverse section of the nerve shows <strong>cut onion appearance</strong></p>\n</td>\n<td>\n<p>Prominent foam cells</p>\n<p>Prominent Grenz zone</p>\n<p>Nerves show concentric perineural cell infiltration<br />and <strong>more conspicuous cut onion appearance</strong>.</p>\n<p>AFB are plentiful, including<br /><strong>small globi</strong></p>\n</td>\n<td>\n<p><strong>Most prominent Grenz zone</strong></p>\n<p><strong>Expansive and loose granulomas</strong></p>\n<p>Plenty of macrophages<br />loaded with AFB- <strong>Virchow cells or Lepra cells</strong></p>\n<p>AFB are seen in endothelial cells and Schwann cells as clumps - <strong>globi</strong></p>\n<p>Nerves are minimally<br />involved.</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8208",
      "difficulty": "medium"
    },
    {
      "text": "A pathologist is studying the split skin smears taken from 4 sites of a leprosy patient. The following findings are noted in the samples. What is the bacteriological index?<div class='question-desc-html'><p>Sample 1 -&nbsp;10 bacilli in 100 oil immersion fields</p>\n<p>Sample 2 -&nbsp;&gt; 1000 bacilli in each oil immersion field</p>\n<p>Sample 3 -&nbsp;10 bacilli in 100 oil immersion fields</p>\n<p>Sample 4 -&nbsp;&gt; 1000 bacilli in each oil immersion field</p>\n<p>&nbsp;</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "3.5"
        },
        {
          "id": 2,
          "text": "4.5"
        },
        {
          "id": 3,
          "text": "5.5"
        },
        {
          "id": 4,
          "text": "2.5"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The <strong>bacteriological index</strong>&nbsp;(BI) of the given samples is <strong>3.5</strong></p>\n<p>According to <strong>Ridley&rsquo;s</strong> <strong>logarithmic</strong> <strong>scale</strong>,&nbsp;&nbsp;&nbsp;</p>\n<ul>\n<li>10 bacilli out of 100 oil immersion fields indicate an index of 1+</li>\n<li>&gt; 1000 bacilli out of average fields imply an index of 6+&nbsp;</li>\n</ul>\n<p>The bacteriological index is calculated by adding the <strong>index from each site</strong> examined and dividing the total by the <strong>number of sites</strong> examined.</p>\n<p>Hence, BI = (1+1+6+6) / 4</p>\n<p>BI = 14/4</p>\n<p>BI = 3.5</p><hr><h3>Related Pearl: Ridley's logarithmic scale in determining Bacterial Index</h3><p>Bacterial Index(BI) indicates the density of the leprosy bacilli in smears and includes both living and dead bacilli.</p>\n<p>According to Ridley's logarithmic scale, the range is from 0 to 6+ and is based on the number of bacilli seen in an average microscopic field of the smear using an oil-immersion objective.</p>\n<table>\n<tbody>\n<tr>\n<td>\n<p>0</p>\n</td>\n<td>\n<p>No bacilli in any of the 100 oil-immersion field</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>1+</p>\n</td>\n<td>\n<p>1-10 bacilli, on average, in 100 oil-immersion field</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>2+</p>\n</td>\n<td>\n<p>1-10 bacilli, on average, in 10 oil-immersion field</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>3+</p>\n</td>\n<td>\n<p>1-10 bacilli, on average, in each oil-immersion field</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>4+</p>\n</td>\n<td>\n<p>10-100 bacilli, on average, in each oil-immersion field</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>5+</p>\n</td>\n<td>\n<p>100-1000 bacilli, on average, in each oil-immersion field&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>6+</p>\n</td>\n<td>\n<p>More than 1000 bacilli, on average, in each oil-immersion field&nbsp;</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>BI is calculated by adding up the index from each site examined and dividing the total by the number of sites examined.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8210",
      "difficulty": "hard"
    },
    {
      "text": "The lepromin test was performed on a patient with suspected leprosy. When will you ask him to come back for interpretation of the test results?",
      "choices": [
        {
          "id": 1,
          "text": "After 24 hrs and on 3rd day"
        },
        {
          "id": 2,
          "text": "After 48hrs and on 7th day"
        },
        {
          "id": 3,
          "text": "After 48 hrs and on 21st day"
        },
        {
          "id": 4,
          "text": "After 24 hrs and on 45th day"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The patient should be asked to come back after <strong>48 hours</strong> and on the&nbsp;<strong>21st day&nbsp;</strong>for interpretation of the test results.</p>\n<p>The <strong>lepromin test</strong> is a skin test for <strong>delayed hypersensitivity</strong> and is the only method to study immunity in leprosy patients. It is performed by injecting 0.1ml of lepromin reagent&nbsp;intradermally&nbsp;into the inner aspect of the forearm. The following 2 reactions are observed:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Early reaction of Fernandez</strong></td>\n<td><strong>Late reaction of Mitsuda</strong></td>\n</tr>\n<tr>\n<td>Develops in&nbsp;24-48 hours&nbsp;</td>\n<td>Starts at 7-10 days, peaks at 3-4 weeks (read on day 21)</td>\n</tr>\n<tr>\n<td>Remains for 3-5 days</td>\n<td>Gradually subsides over the next few weeks</td>\n</tr>\n<tr>\n<td>Poorly defined erythema and induration. Carries less significance</td>\n<td>Considered positive if there is a nodule &gt; 5 mm in diameter</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8202",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is false about the lepromin test?",
      "choices": [
        {
          "id": 1,
          "text": "It is negative in most children in the first 4 months of life"
        },
        {
          "id": 2,
          "text": "It can be used as a diagnostic test"
        },
        {
          "id": 3,
          "text": "It is used to classify leprosy cases"
        },
        {
          "id": 4,
          "text": "False positive may be seen in those who underwent BCG vacination"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The<strong> lepromin test</strong> is not a diagnostic test. It is only used to assess the<strong> immune status</strong>, <strong>classify</strong> the cases, and estimate the <strong>prognosis</strong>.</p>\n<p>The two main drawbacks of this test are:&nbsp;</p>\n<ol>\n<li aria-level=\"1\"><strong>False-positive</strong> results in those who received BCG vaccination</li>\n<li aria-level=\"1\"><strong>False-negative</strong> results in lepromatous and borderline lepromatous cases</li>\n</ol>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8199",
      "difficulty": "easy"
    },
    {
      "text": "A group of public health workers is trying to identify trachoma cases at an ophthalmology camp. Which of the following is the best index to assess for trachoma inflammation?",
      "choices": [
        {
          "id": 1,
          "text": "Follicles on the upper tarsal conjuctiva"
        },
        {
          "id": 2,
          "text": "Limbal follicles and Herbert's pits"
        },
        {
          "id": 3,
          "text": "Presence of trichiasis and entropion"
        },
        {
          "id": 4,
          "text": "Vascular pannus at the superior limbus"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>In epidemiological studies, the <strong>upper tarsal conjunctiva</strong> is the <strong>best index</strong> of <strong>trachomatous</strong> <strong>inflammation</strong> in the eye.</p>\n<p>For the purpose of diagnosis, <strong>any 2</strong> of the following <strong>diagnostic criteria</strong> must be present:</p>\n<ul>\n<li aria-level=\"1\">Follicles on the upper tarsal conjunctiva</li>\n<li aria-level=\"1\">Limbal follicles and Herbert's pits</li>\n<li aria-level=\"1\">Typical conjunctival scarring (trichiasis and entropion)</li>\n<li aria-level=\"1\">Vascular pannus, most marked at the superior limbus</li>\n</ul>\n<p> The following image shows follicles on the upper tarsal conjunctiva seen in trachomatous inflammation.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1496d95d2bf84055bcfb00b217adcce3x1024x660.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4996",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is true about the organisms causing trachoma?",
      "choices": [
        {
          "id": 1,
          "text": "Morax- Axenfeld bacillus is the most widespread"
        },
        {
          "id": 2,
          "text": "Gonococcus is the most dangerous organism contributing to the disease process"
        },
        {
          "id": 3,
          "text": "Koch-Weeks bacillus is the most innocuous"
        },
        {
          "id": 4,
          "text": "C. trachomatis type D commonly causes permanent visual damage"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Gonococcus</strong> is the <strong>most dangerous</strong> organism contributing to the disease process in <strong>trachoma.</strong></p>\n<p>Classic endemic trachoma is caused by&nbsp;<strong><em>Chlamydia trachomatis</em></strong> types<strong> A, B, C</strong>. &nbsp;Other pathogenic organisms that contribute to the disease process are:&nbsp;</p>\n<ul>\n<li>Morax-Axenfeld diplobacillus - most innocuous</li>\n<li>Kochs-Weeks bacillus - most widespread</li>\n<li>Gonococcus - most dangerous</li>\n</ul>\n<p>The <strong>types</strong> <strong>D-K</strong>&nbsp;of <em>C. trachomatis</em> are sexually transmitted and<em>&nbsp;</em>cause<em>&nbsp;</em><strong>inclusion conjunctivitis</strong>. It rarely causes permanent vision loss.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC5006",
      "difficulty": "hard"
    },
    {
      "text": "The elimination of neonatal tetanus is defined as:",
      "choices": [
        {
          "id": 1,
          "text": "< 1 case / 100 live births"
        },
        {
          "id": 2,
          "text": "< 1 case / 1000 live births"
        },
        {
          "id": 3,
          "text": "< 1 case / 10,000 live births"
        },
        {
          "id": 4,
          "text": "< 1 case / 1,00,000 live births"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The elimination of neonatal tetanus is defined as <strong>&lt;1 case per 1000 live births</strong> in every district.&nbsp;Maternal and neonatal tetanus (MNT) was eliminated in India in <strong>2015.</strong></p>\n<p>Since July 2018, TT vaccines have been replaced by the&nbsp;<strong>Td vaccine</strong> for dual protection.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC5010",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following diseases is called the 8th day disease?",
      "choices": [
        {
          "id": 1,
          "text": "Trench fever"
        },
        {
          "id": 2,
          "text": "Pertussis"
        },
        {
          "id": 3,
          "text": "Tetanus"
        },
        {
          "id": 4,
          "text": "Scarlet fever"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Neonatal tetanus</strong> is known as the <strong>8th-day disease.</strong>&nbsp;This is because the clinical features are often seen after the 7th day after birth due to infection of the umbilical cord.</p>\n<p>Option A: Trench fever is also called the 5-day fever.</p>\n<p>Option B: Pertussis is called the 100-day cough.</p>\n<p>Option D:&nbsp;Scarlet fever is also known as the 2nd disease.</p><hr><h3>Related Pearl: Skin rashes: 1st to 6th diseases</h3><table>\n<tbody>\n<tr>\n<td>\n<p>1<sup>st</sup> disease</p>\n</td>\n<td>\n<p>Measles</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>2<sup>nd</sup> disease</p>\n</td>\n<td>\n<p>Scarlet fever</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>3<sup>rd</sup> disease</p>\n</td>\n<td>\n<p>Rubella</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>4<sup>th</sup> disease</p>\n</td>\n<td>\n<p>Duke&rsquo;s disease</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>5<sup>th</sup> disease</p>\n</td>\n<td>\n<p>Erythema infectiosum</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>6<sup>th</sup> disease</p>\n</td>\n<td>\n<p>Roseola infantum</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC5013",
      "difficulty": "medium"
    },
    {
      "text": "A 13-year-old girl is brought to the casualty a few hours after being injured by a rusty knife. According to her parents, her course of tetanus vaccination was completed 7 years ago. What is the next best step in management?",
      "choices": [
        {
          "id": 1,
          "text": "Full course of tetanus toxoid"
        },
        {
          "id": 2,
          "text": "Single dose of tetanus toxoid"
        },
        {
          "id": 3,
          "text": "Human tetanus immunoglobulin"
        },
        {
          "id": 4,
          "text": "Human tetanus immunoglobulin and single dose of toxoid"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>This clinical scenario is suggestive of a <strong>contaminated wound</strong> in a patient who received complete immunization against tetanus 7 years ago. She comes under <strong>category B</strong> of tetanus immunization and must be&nbsp;given a single dose of <strong>tetanus toxoid alone</strong>.</p>\n<p>The WHO recommends a 3-dose primary vaccination series with tetanus-diphtheria-containing vaccine followed by 3 booster doses. Ideally, there should be at least 4 years between booster doses.</p><hr><h3>Related Pearl: Post exposure prophylaxis  for tetanus</h3><p>Prophylaxis is given based on patient category:</p>\n<p>A. Full immunization or a booster dose within the past 5 years.</p>\n<p>B. Full immunization or a booster dose &gt; 5 years ago but &lt; 10 years.</p>\n<p>C. Full immunization or a booster dose &gt; 10 years ago.</p>\n<p>D. Unknown or never taken immunization</p>\n<table>\n<tbody>\n<tr>\n<td>Category</td>\n<td>Clean wound</td>\n<td>Unclean wound</td>\n</tr>\n<tr>\n<td>A</td>\n<td>Only wound care</td>\n<td>Only wound care</td>\n</tr>\n<tr>\n<td>B</td>\n<td>Wound care + TT single dose</td>\n<td>Wound care + TT single dose</td>\n</tr>\n<tr>\n<td>C</td>\n<td>Wound care + TT single dose</td>\n<td>Wound care + TT single dose + Human tetanus immunoglobulin&nbsp;</td>\n</tr>\n<tr>\n<td>D</td>\n<td>Wound care + TT complete course</td>\n<td>Wound care + TT complete course + Human tetanus immunoglobulin</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF2499",
      "difficulty": "medium"
    }
  ]
}